Emergent BioSolutions (EBS) to Settle Securities Class Action Litigation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- S&P Global explores potential separation of Capital IQ business
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
September 13, 2024 6:45 AM EDTGAITHERSBURG, Md., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (Emergent or the Company) today announced that it has entered into an agreement to resolve the previously disclosed securities class action litigation pending in the United States District Court for the District of Maryland (In re Emergent BioSolutions Inc. Security Litigation, No. 8:21-cv-00955-DLB). This lawsuit was originally filed in 2021.
Under the terms of the proposed settlement, Emergent will pay $40 million, which will be substantially paid from insurance proceeds, to settle claims brought on behalf of stockholders who purchased Emergents common stock between... More



